Captrust Financial Advisors Buys 18,476 Shares of Zoetis Inc. (NYSE:ZTS)

Captrust Financial Advisors raised its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 23.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 98,701 shares of the company's stock after acquiring an additional 18,476 shares during the quarter. Captrust Financial Advisors' holdings in Zoetis were worth $16,081,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Zoetis during the 4th quarter valued at about $824,321,000. Wellington Management Group LLP raised its holdings in shares of Zoetis by 78.5% in the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock worth $1,133,755,000 after buying an additional 3,059,255 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Zoetis during the 4th quarter worth about $196,651,000. Polen Capital Management LLC lifted its stake in Zoetis by 17.5% during the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock valued at $1,219,237,000 after acquiring an additional 1,116,541 shares during the period. Finally, Capital Research Global Investors acquired a new stake in Zoetis during the 4th quarter worth about $178,688,000. Institutional investors own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of recent analyst reports. Stifel Nicolaus lowered their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Piper Sandler upped their price objective on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. UBS Group lowered their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday. Finally, Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of "Buy" and a consensus price target of $212.13.

Insider Activity at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,862 shares of company stock valued at $312,254. 0.18% of the stock is owned by corporate insiders.

Zoetis Stock Performance

ZTS traded down $1.73 during trading on Friday, hitting $159.96. The stock had a trading volume of 4,243,109 shares, compared to its average volume of 2,491,043. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company's 50-day moving average price is $157.27 and its 200 day moving average price is $166.22. The firm has a market capitalization of $71.37 billion, a P/E ratio of 29.24, a PEG ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company posted $1.38 earnings per share. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.